Home » Stocks » EARS

Auris Medical Holding Ltd. (EARS)

Stock Price: $3.16 USD 0.35 (12.46%)
Updated Mar 5, 2021 4:00 PM EST - Market closed
After-hours: $3.05 -0.11 (-3.48%) Mar 5, 7:59 PM
Market Cap 34.19M
Revenue (ttm) n/a
Net Income (ttm) -6.63M
Shares Out 1.87M
EPS (ttm) -1.33
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 5
Last Price $3.16
Previous Close $2.81
Change ($) 0.35
Change (%) 12.46%
Day's Open 2.89
Day's Range 2.70 - 4.12
Day's Volume 18,683,859
52-Week Range 0.65 - 5.54

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 1 month ago

Hamilton, Bermuda, January 29, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neu...

GlobeNewsWire - 2 months ago

Hamilton, Bermuda, December 7, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neu...

GlobeNewsWire - 3 months ago

Hamilton, Bermuda, December 2, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS) (“Auris” or the “Company”), a clinical-stage company dedicated to developing therapeutics that address important...

Business Insider - 3 months ago

Auris Medical soared as high as 480% on Tuesday after it announced lab-test results that show its nasal spray could protect against the coronavirus. Shares of the Bermuda-based clinical stage ...

InvestorPlace - 3 months ago

EARS stock typically flies under the radar, but today it is getting a boost thanks to trial data from a Covid-19 treatment. The post EARS Stock: Why Auris Medical Shares Are Soaring 450% appea...

Benzinga - 3 months ago

Auris Medical (NASDAQ: EARS) shares are ripping higher on Tuesday after the company reported positive efficacy data for its AM-301 in protecting against Sars COVID-19 infections. Auris Medical...

GlobeNewsWire - 3 months ago

Hamilton, Bermuda, December 1, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neu...

GlobeNewsWire - 3 months ago

Hamilton, Bermuda, November 20, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in ne...

InvestorPlace - 4 months ago

Auris Medical (EARS) news for Tuesday includes the start of enrollment for the second part of a Phase 2 study to treat acute vertigo. The post Auris Medical News: Why EARS Stock Is Soaring 24%...

GlobeNewsWire - 4 months ago

Hamilton, Bermuda, October 13, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neu...

Seeking Alpha - 5 months ago

Auris Medical Holding Ltd. (EARS) CEO Thomas Meyer on Q2 2020 Results - Earnings Call Transcript

GlobeNewsWire - 5 months ago

Hamilton, Bermuda, September 17, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in n...

GlobeNewsWire - 5 months ago

Hamilton, Bermuda, September 11, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in n...

GlobeNewsWire - 5 months ago

Hamilton, Bermuda, September 8, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in ne...

GlobeNewsWire - 6 months ago

Hamilton, Bermuda, September 3, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in ne...

GlobeNewsWire - 6 months ago

Hamilton, Bermuda, August 20, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neur...

GlobeNewsWire - 7 months ago

Hamilton, Bermuda, July 29, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurot...

GlobeNewsWire - 9 months ago

Hamilton, Bermuda, May 26, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neuroto...

GlobeNewsWire - 10 months ago

       Hamilton, Bermuda, April 16, 2020 – Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in ...

GlobeNewsWire - 11 months ago

Hamilton, Bermuda, April 3, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurot...

GlobeNewsWire - 1 year ago

Hamilton, Bermuda, March 5, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurot...

GlobeNewsWire - 1 year ago

Hamilton, Bermuda, February 25, 2020 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neur...

GlobeNewsWire - 1 year ago

Hamilton, Bermuda, January 10, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neu...

GlobeNewsWire - 1 year ago

Hamilton, Bermuda, Dec. 30, 2019 (GLOBE NEWSWIRE) -- Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet med...

GlobeNewsWire - 1 year ago

Hamilton, Bermuda, Oct. 11, 2019 (GLOBE NEWSWIRE) -- Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet med...

GlobeNewsWire - 1 year ago

Hamilton, Bermuda, Sept. 13, 2019 (GLOBE NEWSWIRE) -- Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet me...

GlobeNewsWire - 1 year ago

Hamilton, Bermuda, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet me...

Seeking Alpha - 1 year ago

Auris Medical Holding Ltd. (EARS) CEO Thomas Meyer on Q2 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

Auris Medical Holding AG (EARS) CEO Thomas Meyer on Q4 2018 Results - Earnings Call Transcript

About EARS

Auris Medical Holding, a development-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment and prevention of peripheral and central nervous disorders. The company's Phase 3 programs under the development include Keyzilen (AM-101) for the treatment of acute inner ear tinnitus; and Sonsuvi (AM-111) for the treatment of acute inner ear hearing loss. It is also developing AM-125 that is in Phase 2 clinical trial for the intranasal treatment of acute peripheral vertigo; and AM-201, which is in Phase... [Read more...]

Industry
Biotechnology
IPO Date
Aug 6, 2014
CEO
Thomas Meyer
Employees
8
Stock Exchange
NASDAQ
Ticker Symbol
EARS
Full Company Profile

Financial Performance

Financial Statements